Posted by jrbecker on April 28, 2003, at 11:30:45
This conference sounds interesting. Maybe we can send our own delegate from the board, ha...
05/04/2003 - Psychiatric Drug Discovery Conference to Highlight Schizophrenia, Depression, Bipolar Disorder and Anxiety on June 23-24, 2003 in Princeton, NJ
PRINCETON, N.J., April 4 /PRNewswire/ -- This year's annual "International Psychiatric Drug Discovery & Development" conference will focus on recent advances in CNS discovery and the development of psychopharmacologic therapies by the pharmaceutical and ..
PR via NewsEdge Corporation : PRINCETON, N.J., April 4 /PRNewswire/ -- This year's annual "International Psychiatric Drug Discovery & Development" conference will focus on recent advances in CNS discovery and the development of psychopharmacologic therapies by the pharmaceutical and biotech industries as well as academia in the treatment of schizophrenia, bipolar disorders, depression, obsessive-compulsive disorders, anxiety and other psychiatric research, announces Strategic Research Institute.The comprehensive two-day event, to take place June 23-24, 2003 in Princeton NJ, will feature presentations of novel research by the leading pharmaceutical, biotech, and academic scientists engaged in cutting edge work in these fields.
The focused mix of the participants, optimal size to afford informal discussion and networking, and quality science has made the conference a fixture on the CNS and psychiatric meeting calendars.
The meeting will cover the following sections namely, Target Identification and Validation, The Impact of Genomics in the Discovery of Novel Psychotherapeutics, Novel mGlu and 5HT Receptor Agonists/Antagonists, New Dopaminergic Mechanisms, Neuropeptides, & Advances in NeuroImaging.
The following companies and universities are schedule to present their most recent data: AstraZeneca, Eli Lilly & Company, Aventis, Harvard Medical School & McLean Hospital, Johnson and Johnson, Maryland Psychiatric Research Center, Merck, Merck Sharp & Dohme, NIMH/NIH, Pfizer, Psychiatric Genomics, Sanofi-Synthelabo, Synaptic Pharmaceuticals Corporation, Acadia Pharmaceuticals, Wyeth Research and others.
To request more information, please contact Glenn Pascual at gpascual
srinstitute.com. Please include your name, title, company, mailing address and full contact information.
To inquire on sponsorship/exhibition/media partner opportunities, please contact Mark Alexay at malexay
srinstitute.com.
CONTACT: Glenn A. Pascual Conference Producer, Pharmaceuticals Strategic Research Institute Tel: 212.967.0095, ext 245 Fax: 212.967.7973 gpascual
srinstitute.com
poster:jrbecker
thread:222904
URL: http://www.dr-bob.org/babble/20030423/msgs/222904.html